Asia Oncology Drug Market Outlook to 2019 – Driven by Rising Demand and Intensifying Joint Ventures between Companies” provides a comprehensive analysis of the oncology drug market in Asia. The report covers various aspects such as market size of oncology drugs, segmentation on the basis of therapeutic class, types of cancer, and volume of exports and imports for oncology drugs. The report is useful for pharmaceuticals companies, retail chains, consultants, healthcare professionals and new players venturing in the market. The market is dominated by few global players including Roche, Novartis, Pfizer and others.
Asia Pacific Region
The Oncology drug market in the Asia, which is hugely driven by rising demand and investment level of government, registered revenues of USD ~ million in 2013. With the advent of new oncology drug manufacturers in the industry, the revenues increased by 7.6% compared to 2013 where the total revenues was USD ~ million. Each segment in the anti-cancer drug market is subject to a gamut of different factors such as prevalence rate of specific type of cancer, price cuts and number of players in the market plays an important role in determining their respective revenues.
The oncology drug market of Asia has grown at a CAGR of 4.3% from USD ~ million in’2009 to INR ~ million in 2014. In more developed markets of the Asia-Pacific region, including countries such as Japan and China, the offerings from the market players are expected to be diverse, focused mainly on customized demands. Additionally, the market is predicted to witness expansion in terms of the newer forms of drugs because of rising cancer incidence and growing awareness. The Asia-Pacific oncology drug market is expected to grow at a CAGR of 9.0% from 2015-2019 on account of increasing affluence of consumers towards healthy lifestyles and treatment of cancer in the recent years.
The Asia oncology drug market is dominated by global pharmaceuticals companies that specialize in marketing patented drugs. The market revenues of Roche from sale of anti-cancer drugs have increased noticeably from USD ~ million in 2012 to USD ~ million in 2014, making it the largest player in oncology drug space. Pfizer was the second largest player in 2014. An inclination in the death rates of cancer patients due lack of proper treatment provides a huge opportunity to pharmaceutical companies to deliver effective drugs in the market and thus contributing to higher revenue of anti-cancer drug market.
India
The Oncology drug market in India, which is driven by the development of new alternative therapies, evolving move from chemotherapy to specific cancer targeted therapy, hormone therapy has registered revenues of INR ~ million in 2013. With an entry of new oncology drug manufacturers in the industry, the revenues increased by 65.5% compared to 2013 where the total revenues was INR ~ million. A major factor that has contributed to such a stupendous growth of this market is advances in technologies. Owing to the advancement in technology, the cancer is diagnosed much frequently and thus better treatment can be provided to the patients. The oncology drug market of India has grown at a CAGR of 22.0% from over INR 12 billion in 2009 to INR ~ million in 2014. The main competitors’ in India oncology space includes Cipla Ltd, Sun Pharma Ltd, Dr Reddy Laboratories amongst others. The India oncology drug market is expected to grow at a CAGR of 17.6% from 2015-2019 due to greater influx of patients in cancer care centers due to rising awareness among the people about the right place for best treatment will continue to escalate the growth of oncology treatment in India.
China
Additionally, China has witnessed continuous and substantial rise in the incidence as well as death caused by cancer. This rapid rise has be attributed to factors such as changing lifestyles and dietary patterns, increasing consumption of tobacco, heavy smoking and several other proximate causes. The revenue of oncology market in China increased by 15.0% compared to 2013. The market has grown at a CAGR of 17.3% from USD ~ million in 2009 to USD ~ million in 2014. The market for oncology drugs in China is dominated by local players such as Jiang Su Heng Rui Medicine Co. Ltd, Qilu Pharmaceuticals Co. Ltd and others. The China oncology drug has been anticipated to incline to about USD 30 billion in 2019 from USD ~ billion in 2014. In addition, the share of generic drugs in China Oncology market is expected to rise by a small percentage to around 72% in the year 2019.
The market for oncology drugs in Asia is changing at a rapid rate. Furthermore, new upcoming drugs, investment by government on Healthcare as well as competitive pressures have been significantly changing the market. Revenues from the anti-cancer drug market in the Asia are expected to expand to USD ~ million in 2019 growing with a CAGR of ~% from 2014-2019.
Key Topics Covered in the Report:
 |
| Asia Cancer Drugs Market |
The Oncology drug market in the Asia, which is hugely driven by rising demand and investment level of government, registered revenues of USD ~ million in 2013. With the advent of new oncology drug manufacturers in the industry, the revenues increased by 7.6% compared to 2013 where the total revenues was USD ~ million. Each segment in the anti-cancer drug market is subject to a gamut of different factors such as prevalence rate of specific type of cancer, price cuts and number of players in the market plays an important role in determining their respective revenues.
The oncology drug market of Asia has grown at a CAGR of 4.3% from USD ~ million in’2009 to INR ~ million in 2014. In more developed markets of the Asia-Pacific region, including countries such as Japan and China, the offerings from the market players are expected to be diverse, focused mainly on customized demands. Additionally, the market is predicted to witness expansion in terms of the newer forms of drugs because of rising cancer incidence and growing awareness. The Asia-Pacific oncology drug market is expected to grow at a CAGR of 9.0% from 2015-2019 on account of increasing affluence of consumers towards healthy lifestyles and treatment of cancer in the recent years.
The Asia oncology drug market is dominated by global pharmaceuticals companies that specialize in marketing patented drugs. The market revenues of Roche from sale of anti-cancer drugs have increased noticeably from USD ~ million in 2012 to USD ~ million in 2014, making it the largest player in oncology drug space. Pfizer was the second largest player in 2014. An inclination in the death rates of cancer patients due lack of proper treatment provides a huge opportunity to pharmaceutical companies to deliver effective drugs in the market and thus contributing to higher revenue of anti-cancer drug market.
India
The Oncology drug market in India, which is driven by the development of new alternative therapies, evolving move from chemotherapy to specific cancer targeted therapy, hormone therapy has registered revenues of INR ~ million in 2013. With an entry of new oncology drug manufacturers in the industry, the revenues increased by 65.5% compared to 2013 where the total revenues was INR ~ million. A major factor that has contributed to such a stupendous growth of this market is advances in technologies. Owing to the advancement in technology, the cancer is diagnosed much frequently and thus better treatment can be provided to the patients. The oncology drug market of India has grown at a CAGR of 22.0% from over INR 12 billion in 2009 to INR ~ million in 2014. The main competitors’ in India oncology space includes Cipla Ltd, Sun Pharma Ltd, Dr Reddy Laboratories amongst others. The India oncology drug market is expected to grow at a CAGR of 17.6% from 2015-2019 due to greater influx of patients in cancer care centers due to rising awareness among the people about the right place for best treatment will continue to escalate the growth of oncology treatment in India.
China
Additionally, China has witnessed continuous and substantial rise in the incidence as well as death caused by cancer. This rapid rise has be attributed to factors such as changing lifestyles and dietary patterns, increasing consumption of tobacco, heavy smoking and several other proximate causes. The revenue of oncology market in China increased by 15.0% compared to 2013. The market has grown at a CAGR of 17.3% from USD ~ million in 2009 to USD ~ million in 2014. The market for oncology drugs in China is dominated by local players such as Jiang Su Heng Rui Medicine Co. Ltd, Qilu Pharmaceuticals Co. Ltd and others. The China oncology drug has been anticipated to incline to about USD 30 billion in 2019 from USD ~ billion in 2014. In addition, the share of generic drugs in China Oncology market is expected to rise by a small percentage to around 72% in the year 2019.
The market for oncology drugs in Asia is changing at a rapid rate. Furthermore, new upcoming drugs, investment by government on Healthcare as well as competitive pressures have been significantly changing the market. Revenues from the anti-cancer drug market in the Asia are expected to expand to USD ~ million in 2019 growing with a CAGR of ~% from 2014-2019.
Key Topics Covered in the Report:
- The market size of the oncology drug market in Asia
- The market size of the generic and patented drugs in Asia oncology drug market.
- The market size of the local and global players market Asia oncology drug market.
- The market size of the India oncology and China oncology drug market.
- Market segmentation of the oncology market on the basis of type of cancer, by generic and patented drugs.
- SWOT and Porter Five force Analysis of India and China Oncology Drug market.
- Trends and Development in the Asia oncology drug market.
- Government Regulations in the India and China oncology drug market.
- Competitive landscape detailed company profiles and market share of the major manufacturers of oncology drugs in Asia as well as India, China and others
- Macro Economic factors affecting India and China Oncology drug market.
- Future outlook and projections of Asia Oncology drug market on the basis of – geography.
Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
